This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mishkin, J. D. Articles by Aranda, J. M. Search for Related Content PubMed PubMed Citation Articles by Mishkin, J. D. Articles by Aranda, J. M., Jr

QUARTERLY FOCUS ISSUE: HEART RHYTHM DISORDERS: STATE-OF-THE-ART PAPER

Appropriate Evaluation and Treatment of Heart Failure Patients After Implantable Cardioverter-Defibrillator Discharge

Time to Go Beyond the Initial Shock

Joseph D. Mishkin, MD^_*, Sherry J. Saxonhouse, MD^_*, Gregory W. Woo, MD^_*, Thomas A. Burkart, MD^_*, William M. Miles, MD^_*, Jamie B. Conti, MD^_*, Richard S. Schofield, MD^_*, Samuel F. Sears, PhD and Juan M. Aranda, Jr, MD^_*,_*

^_* Division of Cardiovascular Medicine, University of Florida College of Medicine, Gainesville, Florida
Departments of Psychology and Cardiovascular Sciences, East Carolina University, Greenville, North Carolina

Manuscript received May 15, 2009; revised manuscript received June 25, 2009, accepted July 12, 2009.

^_* Reprints requests and correspondence: Dr. Juan M. Aranda, Jr, Division of Cardiovascular Medicine, University of Florida College of Medicine, 1600 SW Archer Road, Room M421, Gainesville, Florida 32610 (Email: arandjm{at}medicine.ufl.edu).

Multiple clinical trials support the use of implantable cardioverter-defibrillators (ICDs) for prevention of sudden cardiac death in patients with heart failure (HF). Unfortunately, several complicating issues have arisen from the universal use of ICDs in HF patients. An estimated 20% to 35% of HF patients who receive an ICD for primary prevention will experience an appropriate shock within 1 to 3 years of implant, and one-third of patients will experience an inappropriate shock. An ICD shock is associated with a 2- to 5-fold increase in mortality, with the most common cause being progressive HF. The median time from initial ICD shock to death ranges from 168 to 294 days depending on HF etiology and the appropriateness of the ICD therapy. Despite this prognosis, current guidelines do not provide a clear stepwise approach to managing these high-risk patients. An ICD shock increases HF event risk and should trigger a thorough evaluation to determine the etiology of the shock and guide subsequent therapeutic interventions. Several combinations of pharmacologic and device-based interventions such as adding amiodarone to baseline beta-blocker therapy, adjusting ICD sensitivity, and employing antitachycardia pacing may reduce future appropriate and inappropriate shocks. Aggressive HF surveillance and management is required after an ICD shock, as the risk of sudden cardiac death is transformed to an increased HF event risk.

Key Words: implantable cardioverter-defibrillator therapy • heart failure • appropriate shock • inappropriate shock

Abbreviations and Acronyms   ACEI = angiotensin-converting enzyme inhibitor   AF = atrial fibrillation   ATP = antitachycardia pacing   AV = atrioventricular   HF = heart failure   ICD = implantable cardioverter-defibrillator   NYHA = New York Heart Association   RV = right ventricular   SVT = supraventricular tachycardia   VF = ventricular fibrillation   VT = ventricular tachycardia

This article has been cited by other articles:

				M. Guenther, T. Rauwolf, B. Bruggemann, M. Gerlach, N. K. Wassnig, M. Christoph, M. U. Braun, R. H. Strasser, and C. Wunderlich Pre-hospital discharge testing after implantable cardioverter defibrillator implantation: A measure of safety or out of date? A retrospective analysis of 975 patients Europace, February 1, 2012; 14(2): 217 - 223. [Abstract] [Full Text] [PDF]

				J. B. van Rees, C. J. Willem Borleffs, J. Thijssen, M. K. de Bie, L. van Erven, S. C. Cannegieter, J. J. Bax, and M. J. Schalij Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, and survival gain Europace, January 1, 2012; 14(1): 66 - 73. [Abstract] [Full Text] [PDF]

				A. Auricchio, A. Meijer, T. Kurita, E. Schloss, K. Brinkman, M. Claessens-van Ooijen, and L. Sterns Safety, efficacy, and performance of new discrimination algorithms to reduce inappropriate and unnecessary shocks: the PainFree SST clinical study design Europace, October 1, 2011; 13(10): 1484 - 1493. [Abstract] [Full Text] [PDF]

				R. L. Verrier, T. Klingenheben, M. Malik, N. El-Sherif, D. V. Exner, S. H. Hohnloser, T. Ikeda, J. P. Martinez, S. M. Narayan, T. Nieminen, et al. Microvolt T-wave alternans physiological basis, methods of measurement, and clinical utility-consensus guideline by international society for holter and noninvasive electrocardiology. J. Am. Coll. Cardiol., September 20, 2011; 58(13): 1309 - 1324. [Abstract] [Full Text] [PDF]

				A. T. Owens and M. Jessup The Year in Heart Failure J. Am. Coll. Cardiol., April 12, 2011; 57(15): 1573 - 1583. [Full Text] [PDF]

				S. F. Sears, J. D. Hauf, K. Kirian, G. Hazelton, and J. B. Conti Posttraumatic Stress and the Implantable Cardioverter-Defibrillator Patient: What the Electrophysiologist Needs to Know Circ Arrhythm Electrophysiol, April 1, 2011; 4(2): 242 - 250. [Full Text] [PDF]

				I. Battipaglia, L. Barone, L. Mariani, F. Infusino, R. Remoli, G. Careri, G. Pinnacchio, P. Tarzia, G. A. Lanza, and F. Crea Relationship between cardiac autonomic function and sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillators Europace, December 1, 2010; 12(12): 1725 - 1731. [Abstract] [Full Text] [PDF]